Literature DB >> 16177781

Structures of complement component C3 provide insights into the function and evolution of immunity.

Bert J C Janssen1, Eric G Huizinga, Hans C A Raaijmakers, Anja Roos, Mohamed R Daha, Kristina Nilsson-Ekdahl, Bo Nilsson, Piet Gros.   

Abstract

The mammalian complement system is a phylogenetically ancient cascade system that has a major role in innate and adaptive immunity. Activation of component C3 (1,641 residues) is central to the three complement pathways and results in inflammation and elimination of self and non-self targets. Here we present crystal structures of native C3 and its final major proteolytic fragment C3c. The structures reveal thirteen domains, nine of which were unpredicted, and suggest that the proteins of the alpha2-macroglobulin family evolved from a core of eight homologous domains. A double mechanism prevents hydrolysis of the thioester group, essential for covalent attachment of activated C3 to target surfaces. Marked conformational changes in the alpha-chain, including movement of a critical interaction site through a ring formed by the domains of the beta-chain, indicate an unprecedented, conformation-dependent mechanism of activation, regulation and biological function of C3.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16177781     DOI: 10.1038/nature04005

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  195 in total

1.  Molecular mechanisms of complement evasion: learning from staphylococci and meningococci.

Authors:  Davide Serruto; Rino Rappuoli; Maria Scarselli; Piet Gros; Jos A G van Strijp
Journal:  Nat Rev Microbiol       Date:  2010-06       Impact factor: 60.633

2.  Convertase inhibitory properties of Staphylococcal extracellular complement-binding protein.

Authors:  Ilse Jongerius; Brandon L Garcia; Brian V Geisbrecht; Jos A G van Strijp; Suzan H M Rooijakkers
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

3.  Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex.

Authors:  Nick S Laursen; Kasper R Andersen; Ingke Braren; Edzard Spillner; Lars Sottrup-Jensen; Gregers R Andersen
Journal:  EMBO J       Date:  2011-01-07       Impact factor: 11.598

4.  A highly unusual thioester bond in a pilus adhesin is required for efficient host cell interaction.

Authors:  Jonathan A Pointon; Wendy D Smith; Gerhard Saalbach; Allister Crow; Michael A Kehoe; Mark J Banfield
Journal:  J Biol Chem       Date:  2010-08-19       Impact factor: 5.157

Review 5.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

6.  Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18.

Authors:  Osama A Hamad; Ioannis Mitroulis; Karin Fromell; Huda Kozarcanin; Triantafyllos Chavakis; Daniel Ricklin; John D Lambris; Kristina N Ekdahl; Bo Nilsson
Journal:  Thromb Haemost       Date:  2015-08-13       Impact factor: 5.249

Review 7.  Reverse engineering the ultrasound contrast agent.

Authors:  Mark A Borden; Kang-Ho Song
Journal:  Adv Colloid Interface Sci       Date:  2018-10-24       Impact factor: 12.984

Review 8.  The role of complement in danger sensing and transmission.

Authors:  Jörg Köhl
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

9.  Structural transitions of complement component C3 and its activation products.

Authors:  Noritaka Nishida; Thomas Walz; Timothy A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-15       Impact factor: 11.205

10.  Dynamic structural changes during complement C3 activation analyzed by hydrogen/deuterium exchange mass spectrometry.

Authors:  Michael C Schuster; Daniel Ricklin; Krisztián Papp; Kathleen S Molnar; Stephen J Coales; Yoshitomo Hamuro; Georgia Sfyroera; Hui Chen; Michael S Winters; John D Lambris
Journal:  Mol Immunol       Date:  2008-05-05       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.